
Julie Gralow, MD, FACP, FASCO, discusses the strategies and policy changes implemented by ASCO to address the oncology workforce shortage.

Your AI-Trained Oncology Knowledge Connection!


Julie Gralow, MD, FACP, FASCO, discusses the strategies and policy changes implemented by ASCO to address the oncology workforce shortage.

Julie R. Gralow, MD, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Care Center, University of Washington School of Medicine, discusses future research into bisphosphonates in breast cancer.

Julie R. Gralow, MD, discusses an analysis of the phase III SWOG S0307 trial comparing toxicities and patient-stated preference for oral versus intravenous delivery of bisphosphonates as adjuvant therapy in primary breast cancer.

Julie R. Gralow, MD, gives an overview of a phase II study of adjuvant paclitaxel and trastuzumab (APT trial) for node-negative, HER2-positive breast cancer.

Published: January 24th 2014 | Updated:

Published: October 15th 2014 | Updated:

Published: June 3rd 2014 | Updated: